Add Row
Add Element
cropper
update
National Cannabis Newswire
update
Add Element
  • Home
  • Categories
    • news
    • trends
    • insights
    • industry
    • legalization
    • health
    • culture
    • advocacy
    • Brands
    • New Mexico Dispensaries
    • Arizona Dispensaries
February 11.2026
2 Minutes Read

Can Breathe Life Sciences Dominate the UK Pastilles Market Like in Australia?

Oil dropper with amber glass bottle and cannabis leaves, UK market.

The Rise of Pastilles in Australia: A Game Changer for Medical Cannabis

In recent years, Australia has established itself as a leader in the medical cannabis market, with pastilles becoming a significant player in this transformation. According to the Therapeutic Goods Association (TGA), a notable surge occurred between 2024 and 2025, with pastilles gaining over 25% market share, thus overtaking oils to secure their place as the second most prescribed dosing form. This shift has been revolutionary, driven particularly by companies like Breathe Life Sciences (BLS), which have introduced high-quality products aimed at the needs of patients.

Sam Watson's Vision: Manufacturing Success in Two Markets

After its inception in the UK’s CBD market in 2018, CEO Sam Watson transitioned BLS to Australia to tap into its budding medical cannabis environment. Watson's innovative approach has resulted in remarkable growth. With the establishment of what may be the largest Good Manufacturing Practice (GMP) cannabis gummy production facility, BLS can produce up to three million pastilles monthly, showcasing its ambition to dominate the market. “We were the first company in Australia to launch medicated pastilles, gummies, and we pretty much built that segment in Australia,” he stated proudly.

Bridging Markets: The UK Opportunity

As the pastilles market in Australia flourishes, Watson eyes a similar opportunity in the UK. With the knowledge gained from his successful ventures and a robust production system, he aims to replicate this model across the pond. Leveraging a digital quality management system that minimizes paperwork and enhances efficiency, BLS is well-positioned to break into the UK’s cannabis market. Watson believes that they can not only fill a gap but also pioneer an innovative segment consistent with British consumers' needs.

The Future of Medical Cannabis in the UK: A Vibrant Landscape Awaits

The growing acceptance of cannabis in various formats provides a fertile ground for introduction in the UK. With traditional methods like oils being overshadowed by new alternatives such as pastilles, the landscape is primed for innovation. Watson’s ambition to enrich the UK market with high-quality pastilles comes at a pivotal moment; the medicinal cannabis culture continues evolving, and BLS possesses the unique positioning to influence this journey.

A Community-Centric Approach: Fostering Connections in the Cannabis Sphere

Beyond manufacturing, BLS emphasizes building relationships within the community, engaging stakeholders at every level. By collaborating with local health professionals, educators, and patients, the company seeks to deepen its understanding of consumer desires and improve its offerings. The personal narratives and experiences of community members shape BLS's mission, promising a cannabis landscape that is responsive, inclusive, and continually evolving.

As the UK prepares to welcome this innovative leap, executive cannabis professionals must stay informed and adaptable. The shift from oils to pastilles signifies not just a trend but a change in patient preference and regulatory acceptance. This transition presents opportunities for growth, collaboration, and advancements within the industry.

Brands

16 Views

0 Comments

Write A Comment

*
*
Please complete the captcha to submit your comment.
Related Posts All Posts

How Will DEA Navigate Cannabis Rescheduling Without A Judge?

Update The Push for Cannabis Rescheduling: What’s at Stake?The debate surrounding cannabis rescheduling continues to escalate, with lawmakers growing increasingly frustrated over the lack of movement from the Drug Enforcement Administration (DEA). Representative Steve Cohen (D-TN) has boldly questioned how the DEA intends to reschedule cannabis from a Schedule I to a Schedule III substance without an Administrative Law Judge (ALJ) to oversee the legalities involved. With the deadline set forth in the HALT Fentanyl Act long passed, advocates for cannabis reform face an uphill battle as the administration remains largely silent.Understanding the Implications of ReschedulingRescheduling cannabis could mark a transformative shift in federal drug policy, acknowledging its medical benefits while simultaneously imposing regulations that could enhance its accessibility for research and therapeutic use. The DEA’s proposed rule would significantly change the status quo, easing access for researchers who have been hampered by the stringent controls associated with Schedule I substances. This transition acknowledges the evolving perspective on cannabis as a legitimate medicinal product, rather than a controlled substance with no medical value—an understanding that has taken root over several decades.The Historical Context: A Long-Standing StalemateCalls for cannabis reform date back over 50 years, spearheaded by the recommendations from the Nixon-era Shafer Commission. Despite overwhelming public support and legislative momentum at the state level, the federal government has yet to align its policies with reality. Cohen's reflections on this historical backdrop emphasize the disconnect that continues to persist, leading many industry experts to speculate that internal resistance within the DEA may be impeding progress.Challenges Ahead: The Role of Current LeadershipThe void left by the retirement of DEA Chief Administrative Law Judge John Mulrooney casts a pall over the rescheduling efforts. Representative Cohen's pointed inquiry about how the rescheduling will proceed without leadership in place reveals critical gaps and highlights the urgency for institutional action. This leadership turmoil poses significant challenges, raising questions about the efficacy of current political will to advance cannabis policy reform.The Future of Cannabis Policy: What’s Next?Looking ahead, rescheduling cannabis isn't merely a bureaucratic hurdle; it could influence various issues ranging from research funding to tax implications for cannabis businesses. As the landscape evolves, understanding the balance between state and federal regulations will become crucial. Should the administration choose to prioritize rescheduling, it may eventually lead to a reevaluation of cannabis at the federal level, paving the way for deeper reforms that address social justice issues and foster economic growth within the legal cannabis sector.Your Voice Matters: Engage in the ConversationThe ongoing discussions and debates around cannabis rescheduling are vital but ultimately hinge on public engagement and advocacy. Industry professionals, policymakers, and citizens alike have a role to play in shaping a future that harmonizes federal law with evolving public sentiment on cannabis. As stakeholders, being informed and actively participating in dialogues surrounding these changes can help drive the necessary momentum towards a more rational and equitable cannabis policy.

White House Meetings Aim to Resolve CBD Compliance and Enforcement Policy

Update The Urgent Need for Clarity in the CBD Landscape The cannabis industry is at a pivotal point with upcoming meetings between the White House and industry executives. As the clock ticks towards the November 2026 enforcement of new hemp regulations, the industry is left in a state of uncertainty after the FDA missed its 90-day deadline to clarify which cannabinoids will be affected by the upcoming restrictions. In the backdrop of tens of billions of dollars being at stake, the meetings scheduled for early April are crucial to establish a cohesive regulatory framework for CBD aimed at both protecting consumer safety and supporting responsible business practices. Understanding the Implications of the New Legislation Passed in November 2025, the recent legislation aims to reign in the loosely regulated intoxicating hemp sector. It proposes to subject intoxicating hemp products to the same criminal and collateral issues as marijuana, impacting nearly 95% of the industry. Industry analysts, like Deb Tharp, emphasize that this could severely hinder legitimate businesses focused on non-intoxicating products like CBD. As many fear, the legislation may classify extraction tanks as holding controlled substances unless clarity is achieved on terms such as 'container'. The complexity deepens without specific guidance on the boundaries of non-intoxicating products amid possible THC level misinterpretations. FDA and White House Dynamics: What Can We Expect? Three key meetings have been organized to discuss the FDA’s new proposed rule, titled ‘Cannabidiol (CBD) Products Compliance and Enforcement Policy.’ Scheduled for April 1st and 2nd, the focus will be on what might emerge from the FDA’s submission to OIRA for review. Although it is uncertain whether the FDA will address the pressing needs raised by the new legislation, or if it will conform to President Trump’s earlier executive order advocating a clear pathway for CBD regulation, stakeholders remain hopeful that these discussions will shape more informed policy responses. The Stock Market and Financial Access: A New Era? In tandem with these developments, US cannabis companies may soon gain access to NASDAQ and other financial services under the newly proposed bill, creating significant shifts in industry standards and engagement. This could pave the way for better banking relations, increased investment opportunities, and a more legitimate business landscape. A more standardized regulatory environment could enhance consumer trust and facilitate market growth, ensuring safer products for consumers. Under such a framework, cannabis businesses would benefit from increased transparency and reliability, which is essential for gaining consumer confidence. Closing Thoughts: Why This Matters To You For executives in the cannabis industry, these meetings and subsequent regulations come at a crucial juncture. How the FDA and White House navigate the future of CBD enforcement could significantly alter the operational landscape and market positioning of businesses across the country. As these discussions unfold, staying informed and proactive is vital. With the evolving nature of cannabis regulations, cannabis professionals must gear up to adapt not just to compliance but to thriving under a new operational mandate. Keep an eye on updates from these key meetings; your business may depend on it!

Melt-to-Make Patented Gummy Base Technology Supports Scalable Cannabis Edibles Manufacturing 

FOR IMMEDIATE RELEASE Cannabis / Nutraceuticals / Manufacturing / Patent / Gummies / Growth / Scaling “Our focus has been on removing unnecessary complexity from edible manufacturing,” said Sarah McLaughlin, MS, RD, co-founder and vice president at Melt-to-Make. NORTHAMPTON, Mass. — February 20, 2026 — As the global cannabis edibles market continues to expand, manufacturers are facing growing pressure to deliver compliant, consistent, and scalable products. According to Fortune Business Insights, the cannabis edibles market is projected to exceed $55 billion by 2034, reflecting sustained double-digit compound annual growth.The expanding market is increasing demand for manufacturing systems that reduce formulation variability while improving production efficiency. In response, many producers are adopting standardized formulation platforms to support reliable output across product lines, facilities, and geographic markets. Melt-to-Make has introduced a patented gelatin and pectin gummy base technology designed to address persistent bottlenecks in large-batch edible production. The company’s shelf-stable semi-finished gummy base can be heated and infused with active ingredients before molding, helping manufacturers simplify workflows while improving repeatability.By standardizing the gummy base, the Melt-to-Make system reduces common manufacturing challenges associated with traditional confectionery production, including inconsistent texture, lengthy research and development cycles, and batch failures during scale-up.“Our focus has been on removing unnecessary complexity from edible manufacturing,” said Sarah McLaughlin, MS, RD, co-founder and vice president of product development and research at Melt-to-Make. “When the formulation system itself is consistent and repeatable, manufacturers can concentrate on dosing precision and operational efficiency rather than troubleshooting structure and texture.” Traditional gummy production often requires specialized confectionery equipment and advanced formulation expertise, particularly when working with pectin in vegan and heat-stable applications. Melt-to-Make’s semi-finished gummy base is designed to integrate into existing production workflows, giving manufacturers a more standardized substrate for predictable results.As regulated cannabis markets in the United States and Europe continue implementing stricter quality control and labeling standards, consistency in edible production is becoming increasingly important for both regulatory compliance and long-term brand reliability.Standardized ingredient systems are emerging as a practical solution for achieving repeatable performance in expanding markets. Melt-to-Make currently serves clients in more than 15 countries and provides technical documentation, formulation tools, and production support for manufacturers implementing the technology.To learn more, visit www.melt-to-make.com. About Melt-to-Make™ Founded in 2018 in Northampton, Massachusetts, by Sarah McLaughlin, Jake Goodyear, and Tim Van Epps, Melt-to-Make™ specializes in innovative gummy base systems designed to simplify large-batch gummy manufacturing. By offering professionally formulated gelatin and pectin bases that are approximately 90% complete, the company helps manufacturers produce gummies faster, more efficiently, and with greater consistency.Melt-to-Make™ is committed to using all-natural ingredients and colors while supporting a wide range of consumer preferences, including vegan, gluten-free, and non-GMO options. The company serves more than 1,000 B2B customers across the United States and in 15 countries, offering comprehensive support that includes equipment lists, training videos, custom formulations, and on-site technical assistance.For more information, visit www.melt-to-make.com or call 1-800-241-0341.Media ContactProven Media Kim Prince Phone: 480-221-7995 Email: kim@provenmedia.com

Terms of Service

Privacy Policy

Core Modal Title

Sorry, no results found

You Might Find These Articles Interesting

T
Please Check Your Email
We Will Be Following Up Shortly
*
*
*